Zovighian Bernard J's Form 4 filing
Edwards Lifesciences Corp (EW) · filed May 6, 2025
- Accession no.
- 0001225208-25-004799
- Filed
- May 6, 2025
- Trade date
- May 3-6, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 8 non-derivative transactions and 1 derivative transaction. Open-market sales total $448.0K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zovighian Bernard JCIK 0001665141 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 3, 2025 | Common Stock | FTax withholdingDisposed | −527 | $75.65 | −$39,867.55 | 58,826.55 | Direct | |
| May 4, 2025 | Common Stock | FTax withholdingDisposed | −543 | $75.65 | −$41,077.95 | 58,283.55 | Direct | |
| May 5, 2025 | Common Stock | MOption exerciseAcquired | +7,462 | $45.28 | +$337,879.36 | 65,745.55 | Direct | |
| May 5, 2025 | Common Stock | GGiftDisposed | −1,482 | $0.00 | $0 | 64,263.55 | Direct | |
| May 5, 2025 | Common Stock | SSaleDisposed | −5,980 | $74.91F2 | −$447,961.8 | 58,283.55 | Direct | |
| May 6, 2025 | Common Stock | GGiftDisposed | −1,036 | $0.00 | $0 | 57,247.55 | Direct | |
| May 5, 2025 | Common Stock | GGiftAcquired | +1,482 | $0.00 | $0 | 11,918 | Indirect | |
| May 6, 2025 | Common Stock | GGiftAcquired | +1,036 | $0.00 | $0 | 12,954 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 5, 2025 | Common Stock | MOption exerciseDisposed | −7,462 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $74.67 to $75.15 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.